Luminex Corp and BD, through its BD Diagnostics-TriPath platform, have announced the signing of a development and supply agreement. Under the terms of the agreement, BD Diagnostics-TriPath will develop, market and sell new biomarker-based diagnostic tests for certain cancers using Luminexs multiplexing xMAP Technology platform.
Read More
Supplement October 2008 MRSA Infections Are Problematic, But Is Screening Always a Good Idea?by Lynne Friedmann and Gary TufelTesting for nosocomial infections is growing in importance, with MRSA screening a hot topic SPONSOR
Read MoreQuidel Corporation, a leading provider of rapid point-of-care diagnostic tests, announced today that the QuickVue brand Influenza A+B test is the rapid flu test selected by Roche for use in over 400 physician offices participating in the FluSTAR surveillance program during the 2008-09 season.
Read MoreHospital chargeswhat patients are billed for their rooms, nursing care, diagnostic tests and other servicesjumped from $873 billion in 2005 to $943 billion in 2006, according to the latest News and Numbers from the Agency for Healthcare Research and Quality.
Read MoreA major study from a team of researchers from Weill Cornell Medical College and Massachusetts General Hospital has found that a recent change to HIV-treatment guidelines recommending genetic screening is cost-effective under certain conditions. The new recommendation suggests conducting a genetic screening test prior to prescribing the drug abacavir, one of the preferred first-line drugs for the treatment for HIV-infected adults.
Read More